DelveInsight Business Research LLP

DelveInsight’s “Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Insights, Epidemiology, and Market Forecast-2032″  report delivers an in-depth understanding of the Neuromyelitis Optica Spectrum Disorder (NMOSD), historical and forecasted epidemiology as well as the Neuromyelitis Optica Spectrum Disorder (NMOSD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Neuromyelitis Optica Spectrum Disorder (NMOSD) market report provides current treatment practices, emerging drugs, Neuromyelitis Optica Spectrum Disorder (NMOSD) market share of the individual therapies, current and forecasted Neuromyelitis Optica Spectrum Disorder (NMOSD) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Neuromyelitis Optica Spectrum Disorder (NMOSD) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Neuromyelitis Optica Spectrum Disorder (NMOSD) market.

Some of the key facts of the Neuromyelitis Optica Spectrum Disorder Market Report:

• Cases clinically diagnosed as NMOSD may include aquaporin 4 (AQP4)-antibody-seropositive autoimmune astrocytopathic disease, myelin oligodendrocyte glycoprotein (MOG)-antibody-seropositive inflammatory demyelinating disease, and double-seronegative disease.The  

• The AQP4-antibody disease has a high female-to-male ratio (up to 9:1), and its mean age at onset of ~40 years is later than that seen in multiple sclerosis. For MOG-antibody disease, its gender ratio is closer to 1:1, and it is more common in children than in adults. Its clinical phenotypes differ but overlap with those of AQP4-antibody disease and include acute disseminated encephalomyelitis, brainstem, and cerebral cortical encephalitis, as well as optic neuritis and myelitis.

•  The double-seronegative disease requires further research and clarification. Population-based studies over the past two decades report the prevalence and incidence of NMOSD in different populations worldwide. One relevant finding is the varying prevalence observed in different racial groups. Consistently, the prevalence of NMOSD among Whites is ~1/100,000 population, with an annual incidence of <1/million population. Among East Asians, the prevalence is higher, at ~3.5/100,000 population, while the prevalence in Blacks may be up to 10/100,000 population. For MOG-antibody disease, hospital-based studies largely do not observe any significant racial preponderance so far. 

• This disorder comprises a significant proportion of NMOSD cases that are AQP4-antibody-seronegative. A recent Dutch nationwide study reported the annual incidence of MOG-antibody disease as 1.6/million population (adult: 1.3/million, children: 3.1/million).

Key benefits of the Neuromyelitis Optica Spectrum Disorder Market report:

• The report covers the descriptive overview of Neuromyelitis Optica Spectrum Disorder (NMOSD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

• Comprehensive insight has been provided into the Neuromyelitis Optica Spectrum Disorder (NMOSD) epidemiology and treatment in the 7MM

• Additionally, an all-inclusive account of both the current and emerging therapies for Neuromyelitis Optica Spectrum Disorder (NMOSD) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

• A detailed review of the Neuromyelitis Optica Spectrum Disorder (NMOSD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market

Got queries? Click here to know more about the Neuromyelitis Optica Spectrum Disorder Landscape

Neuromyelitis Optica Spectrum Disorder Market Overview

The Neuromyelitis Optica Spectrum Disorder (NMOSD) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Neuromyelitis Optica Spectrum Disorder (NMOSD) market trends by analyzing the impact of current Neuromyelitis Optica Spectrum Disorder (NMOSD) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Neuromyelitis Optica Spectrum Disorder (NMOSD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Neuromyelitis Optica Spectrum Disorder (NMOSD) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Neuromyelitis Optica Spectrum Disorder (NMOSD) market in 7MM is expected to witness a major change in the study period 2019-2032.

Neuromyelitis Optica Spectrum Disorder Market Epidemiological Insights:

• Consistently, the prevalence of NMOSD among Whites is ~1/100,000 population, with an annual incidence of <1/million population. 

• Among East Asians, the prevalence is higher, at ~3.5/100,000 population, while the prevalence in Blacks may be up to 10/100,000 population. 

• For MOG-antibody disease, hospital-based studies largely do not observe any significant racial preponderance so far.

•  This disorder comprises a significant proportion of NMOSD cases that are AQP4-antibody-seronegative. A recent Dutch nationwide study reported the annual incidence of MOG-antibody disease as 1.6/million population (adult: 1.3/million, children: 3.1/million). 

• Clinical and radiological differences between AQP4-antibody and MOG-antibody

Neuromyelitis Optica Spectrum Disorder Market Epidemiological Segmentation 

• Neuromyelitis Optica Spectrum Disorder total diagnosed cases 

• Neuromyelitis Optica Spectrum Disorder total treatment-related cases

Neuromyelitis Optica Spectrum Disorder Market Outlook 

The report’s Neuromyelitis Optica Spectrum Disorder market outlook helps to better understand the historic, current and forecasted Neuromyelitis Optica Spectrum Disorder market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Neuromyelitis Optica Spectrum Disorder market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.

According to DelveInsight, the Neuromyelitis Optica Spectrum Disorder market in 7MM is expected to grow steadily during the study period 2019–2032.

The current management options for Neuromyelitis Optica Spectrum Disorder can be mainly categorized into two categories: curative treatment and symptomatic treatment. Hematopoietic stem cell transplantation (allogenic) is the only available curative treatment for Neuromyelitis Optica Spectrum Disorder, whereas the symptomatic treatment involves administration of granulocyte-colony stimulating factor (G-CSF), exogenous administration of immunoglobulins (IV/subcutaneous), G-CSF, and CXCR4 antagonists.

The major market players in Neuromyelitis Optica Spectrum Disorder therapeutic market are Amgen, Sandoz (Novartis), Pfizer, Takeda, and X4 Pharmaceuticals, among others.

Learn more by requesting for sample @Neuromyelitis Optica Spectrum Disorder Market Landscape

Neuromyelitis Optica Spectrum Disorder Key Companies:  

• Hoffmann La Roche 

• Chugai Pharma 

• Horizon Pharma 

• Beijing Mabworks Biotech Co.ltd.

• Nihon Pharma 

• RemeGen Co. Ltd

• And many others 

Table of Contents

•  Key Insights 

•  Report Introduction 

•  Executive Summary of Neuromyelitis Optica Spectrum Disorder

•  Disease Background and Overview

•  Epidemiology and patient population

•  The United States 

•  EU 5

•  Neuromyelitis Optica Spectrum Disorder Emerging Therapies

•  Neuromyelitis Optica Spectrum Disorder Market Outlook

•  Market Access and Reimbursement of Therapies

•  Appendix

•  Neuromyelitis Optica Spectrum Disorder  Report Methodology

•  DelveInsight Capabilities

• Disclaimer

Click here to read more about Neuromyelitis Optica Spectrum Disorder Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/